Warm Autoimmune hemolytic anemia (WAIHA) Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Rigel Pharma, Incyte Crp., Sanofi, Johnson & Johnson, Janssen R&D

Posted on
by

Warm Autoimmune hemolytic anemia (WAIHA) Market Poised for Significant Growth from 2024 to 2034, Reports DelveInsight | Rigel Pharma, Incyte Crp., Sanofi, Johnson & Johnson, Janssen R&D
The Key Warm Autoimmune hemolytic anemia Companies in the market include – Zenas BioPharma, Novartis, MorphoSys, Alpine Immune Sciences, Rigel Pharma, Incyte Corp, Sanofi, Johnson & Johnson, Janssen Research & Development, Annexon, Inc., Apellis Pharma, Rigel Pharmaceuticals, Hutchison Medipharma Limited, and others.

DelveInsight’s “Warm Autoimmune hemolytic anemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Warm Autoimmune hemolytic anemia, historical and forecasted epidemiology as well as the Warm Autoimmune hemolytic anemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Warm Autoimmune hemolytic anemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Warm Autoimmune hemolytic anemia Market Forecast

 

Some of the key facts of the Warm Autoimmune hemolytic anemia Market Report:

  • The Warm Autoimmune hemolytic anemia market size was valued approximately USD 300 Million in the year 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

  • In February 2024, Novartis declared its intention to initiate a voluntary public takeover bid to acquire MorphoSys through an agreement.

  • The total market size for wAIHA in the US was estimated at approximately USD 200 million in 2023, with expectations for growth during the forecast period (2024–2034).

  • In 2023, Germany held the largest market share for wAIHA in the EU4 and the UK, with a market size of USD 20 million, and this is projected to grow during the forecast period (2024–2034).

  • By 2034, Nipocalimab (M281) is expected to generate the highest revenue among emerging therapies for wAIHA in Japan.

  • In 2023, the US had the highest number of prevalent cases of autoimmune hemolytic anemia among the 7MM, with approximately 57,000 cases. This figure is expected to rise throughout the forecast period.

  • In 2023, females represented a significant portion of gender-specific prevalent cases of wAIHA, accounting for up to 60% of cases. These cases are projected to rise by 2034 in the US.

  • In 2023, Germany reported the highest number of prevalent cases of wAIHA among the EU4 and the UK, while Spain had the lowest.

  • Estimates indicate that in Japan, the highest prevalence of wAIHA was observed in the ≥65 age group, making up over 64% of total cases in 2023.

  • Key Warm Autoimmune hemolytic anemia Companies: Zenas BioPharma, Novartis, MorphoSys, Alpine Immune Sciences, Rigel Pharma, Incyte Corp, Sanofi, Johnson & Johnson, Janssen Research & Development, Annexon, Inc., Apellis Pharma, Rigel Pharmaceuticals, Hutchison Medipharma Limited, and others

  • Key Warm Autoimmune hemolytic anemia Therapies: Obexelimab (ZB012), Ianalumab, Povetacicept, Fostamatinib, Parsaclisib, Rilzabrutinib, Nipocalimab, M281, ANX005, APL-2, Fostamatinib disodium, HMPL-523(300mg PO QD), and others

  • The Warm Autoimmune hemolytic anemia epidemiology based on gender analyzed that in case of Warm Autoimmune hemolytic anemia, gender ratio revealed preponderance of the female gender over the male counterpart

  • The Warm Autoimmune hemolytic anemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Warm Autoimmune hemolytic anemia pipeline products will significantly revolutionize the Warm Autoimmune hemolytic anemia market dynamics.

 

Warm Autoimmune hemolytic anemia Overview

Warm Autoimmune Hemolytic Anemia (WAIHA) is a condition where the immune system mistakenly attacks and destroys its own red blood cells at normal body temperatures. This leads to anemia, a shortage of red blood cells, causing symptoms like fatigue, pale skin, jaundice, and an increased heart rate. The exact cause of WAIHA is often unknown but can be linked to other conditions, such as autoimmune disorders, infections, or certain medications. Treatment typically involves managing the underlying cause, medications to suppress the immune system, and in some cases, blood transfusions.

 

Get a Free sample for the Warm Autoimmune hemolytic anemia Market Report:

https://www.delveinsight.com/report-store/warm-autoimmune-hemolytic-anemia-waiha-market

 

Warm Autoimmune hemolytic anemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Warm Autoimmune hemolytic anemia Epidemiology Segmentation:

The Warm Autoimmune hemolytic anemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Warm Autoimmune hemolytic anemia

  • Prevalent Cases of Warm Autoimmune hemolytic anemia by severity

  • Gender-specific Prevalence of Warm Autoimmune hemolytic anemia

  • Diagnosed Cases of Episodic and Chronic Warm Autoimmune hemolytic anemia

 

Download the report to understand which factors are driving Warm Autoimmune hemolytic anemia epidemiology trends @ Warm Autoimmune hemolytic anemia Epidemiology Forecast

 

Warm Autoimmune hemolytic anemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Warm Autoimmune hemolytic anemia market or expected to get launched during the study period. The analysis covers Warm Autoimmune hemolytic anemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Warm Autoimmune hemolytic anemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Warm Autoimmune hemolytic anemia Therapies and Key Companies

  • Obexelimab (ZB012): Zenas BioPharma

  • Ianalumab: Novartis/MorphoSys

  • Povetacicept: Alpine Immune Sciences

  • Fostamatinib: Rigel Pharmaceuticals

  • Parsaclisib: Incyte Corporation

  • Rilzabrutinib: Sanofi

  • Nipocalimab: Johnson & Johnson

  • M281: Janssen Research & Development

  • ANX005: Annexon, Inc.

  • APL-2: Apellis Pharmaceuticals, Inc.

  • Fostamatinib disodium: Rigel Pharmaceuticals

  • HMPL-523(300mg PO QD): Hutchison Medipharma Limited

 

Discover more about therapies set to grab major Warm Autoimmune hemolytic anemia market share @ Warm Autoimmune hemolytic anemia Treatment Market

 

Warm Autoimmune hemolytic anemia Market Drivers

  • Increasing patient population

  • Advancement in research and development

  • Improved clinical trials

  • Patient assistance programs

  • New therapeutic agents

 

Warm Autoimmune hemolytic anemia Market Barriers

  • Increasing refractory cases

  • Associated co-morbidities

  • Unavailability of better treatment options

  • Therapy failure

  • Lack of disease understanding

  • Unavailability of curative treatment

 

Scope of the Warm Autoimmune hemolytic anemia Market Report

  • Study Period: 2020–2034

  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

  • Key Warm Autoimmune hemolytic anemia Companies: Zenas BioPharma, Novartis, MorphoSys, Alpine Immune Sciences, Rigel Pharma, Incyte Corp, Sanofi, Johnson & Johnson, Janssen Research & Development, Annexon, Inc., Apellis Pharma, Rigel Pharmaceuticals, Hutchison Medipharma Limited, and others

  • Key Warm Autoimmune hemolytic anemia Therapies: Obexelimab (ZB012), Ianalumab, Povetacicept, Fostamatinib, Parsaclisib, Rilzabrutinib, Nipocalimab, M281, ANX005, APL-2, Fostamatinib disodium, HMPL-523(300mg PO QD), and others

  • Warm Autoimmune hemolytic anemia Therapeutic Assessment: Warm Autoimmune hemolytic anemia current marketed and Warm Autoimmune hemolytic anemia emerging therapies

  • Warm Autoimmune hemolytic anemia Market Dynamics: Warm Autoimmune hemolytic anemia market drivers and Warm Autoimmune hemolytic anemia market barriers

  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

  • Warm Autoimmune hemolytic anemia Unmet Needs, KOL’s views, Analyst’s views, Warm Autoimmune hemolytic anemia Market Access and Reimbursement

 

To know more about Warm Autoimmune hemolytic anemia companies working in the treatment market, visit @ Warm Autoimmune hemolytic anemia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Warm Autoimmune hemolytic anemia Market Report Introduction

2. Executive Summary for Warm Autoimmune hemolytic anemia

3. SWOT analysis of Warm Autoimmune hemolytic anemia

4. Warm Autoimmune hemolytic anemia Patient Share (%) Overview at a Glance

5. Warm Autoimmune hemolytic anemia Market Overview at a Glance

6. Warm Autoimmune hemolytic anemia Disease Background and Overview

7. Warm Autoimmune hemolytic anemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Warm Autoimmune hemolytic anemia

9. Warm Autoimmune hemolytic anemia Current Treatment and Medical Practices

10. Warm Autoimmune hemolytic anemia Unmet Needs

11. Warm Autoimmune hemolytic anemia Emerging Therapies

12. Warm Autoimmune hemolytic anemia Market Outlook

13. Country-Wise Warm Autoimmune hemolytic anemia Market Analysis (2020–2034)

14. Warm Autoimmune hemolytic anemia Market Access and Reimbursement of Therapies

15. Warm Autoimmune hemolytic anemia Market Drivers

16. Warm Autoimmune hemolytic anemia Market Barriers

17. Warm Autoimmune hemolytic anemia Appendix

18. Warm Autoimmune hemolytic anemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/